Angiotensin II receptor pharmacology and AT1-receptor blockers

Journal of Human Hypertension

Volumn 13, Issue , 1999, Pages S11-S20

  Chung, O ^a   Csikos T ^a   Unger, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Angiotensin II; At1; At1 antagonists; At2; Receptors

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; ARGIPRESSIN; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; EPROSARTAN; IMIDAZOLEACETIC ACID; IRBESARTAN; LOSARTAN; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; SARMESIN; TELMISARTAN; VALSARTAN;

APOPTOSIS; AREA UNDER THE CURVE; BLOOD VESSEL TONE; CELL DIFFERENTIATION; CELL MATURATION; CELL REGENERATION; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG URINE LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MOLECULAR CLONING; NERVE FIBER GROWTH; NONHUMAN; ORAL DRUG ADMINISTRATION; RECEPTOR AFFINITY; RECEPTOR GENE;

ACRYLATES; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TETRAZOLES; THIOPHENES;

EID: 0032905904     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000744     Document Type: Article

References (107)

1. Gohlke P Cardiac and vascular effects of longterm Losarían treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996; 28: 397-402.
2. Schieffer B Comparative effects of chronic angiot- ensin-converting enzyme inhibition and Ang II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994; 89: 2273- 2282.
3. Remuzzi A Comparison of the effects of angioten- sin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Exp Nephrol1996; 4: 19-25.
4. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766- 771.
5. Urata H Ang II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890.
6. Urata H identification of a highly specific chym- ase as the major angiotensin-II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
7. Dzau VJ Human neutrophils release serine proteases capable of activating prorenin. Circ Res 1987; 60: 595-601.
8. Wintroub BU, Klickstein LB, Watt KW. A human neutrophil dependent pathway for generation of Ang II.; Clin Invest 1981; 68: 484-490.
9. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes; physiological and pharmacological implications. J Hypertens 1993; 11 (Suppl 3): S13-S18.
10. Boucher R, Asselin JH, Genest J. A new enzyme leading to direct formation of angiotensin II. Circ Res 1994; 34 (Suppl 1): 1203-1209.
11. Linz W Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
12. Pals DT et al. Role of the pressor action of Ang II in experimental hypertension. Circ Res 1971; 29: 673- 681.
13. Anderson GH, Streeten DHP, Dalakas TG. Pressor responses to l-Sar-8-Ala-Ang II (saralasin) in hypertensive subjects. Circ Res 1977; 40: 243-250.
14. Case DB, Wallace JM, Larach JH. Comparison between saralasin and converting enzyme inhibitor in hypertensive disease. Kidney Int 1979; 15: S107-S114.
15. Furukawa Y, Kishimoto S, Nishikawa K. Hypotensive imidazole derivatives and hypotensive imidazole-5- acetic acid derivatives. Patents issued to Takeda Chemical Industries Ltd on July 20, 1982, and October 19, 1982, respectively, U.S. Patents 4,340,598 and 4,355,040. Osaka, Japan.
16. Bovee KC, Wong PC, Timmermans PBMWM, Thoolen MJMC. Effects of nonpeptide Ang II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens1991; 4 (Part 2): 327S-333S.
17. Goa KL, Wagstaff AJ. Losarían Potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Dnigs 1996; 51: 820-845.
18. Ohtawa M, Takayama F, Saitoh K. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losarían, an orally active nonpeplide Ang II receptor anlagonisl, in humans. Br J Clin Pharmacol 1993; 35: 290-297.
19. Siegl PKS. Discovery of losarían, ihe firsl specific nonpeplide Ang II receptor antagonist. J Hypertens 1993; 11 (Suppl 3): S19-S22.
20. Criscione L et al. Valsartan, Preclinical and clinical profile of an antihypertensive angiolensin-II aniagon- isl. Cardiovasc Drug Rev 1995; 13: 230-250.
21. Criscione L Pharmacological profile of valsarían: A potent, orally active, nonpeptide antagonist of the Ang II ATI-receptor subtype. Br J Pharmacol 1993; 110: 761-771.
22. De Gasparo M, Whitebread S. Binding of valsarían to mammalian ATI-receptors. Regni Pept 1995; 59: 303-311.
23. Müller P Ang II receptor blockade with single doses of valsarían in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231-245.
24. Cazaubon C In vitro and in vivo pharmacology of SR47436, an Ang II receptor antagonist. Am J Hyper- tens 1992; 5 (Part 2): 19A-20A.
25. Martinez F Effect of SR 47436 (BMS-186295) on renal hemodynamics and on glomerular permselectiv- ity in health humans. J Am Soc Nephrol 1994; 5: 607.
26. Nisato D Pharmacological properties of SR 47436, a non-peptidic Ang II receptor antagonist. Br J Pharmacol 1992; 105: 84P.
27. Ribstein J Effects of the angiotensin II antagonist SR 47436 (BMS-186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens1994; 12: 131.
28. Delacretaz E Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21.
29. Edwards RM Pharmacological characterization of the nonpeptide Ang II receptor antagonist, SK F108566. J Pharmacol Exp Ther 1992; 260: 175-181.
30. Strohmenger HU, Lindner KH, Wienen W, Vogt J. Effects of the ATI-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs. Resuscitation 1997; 35 (1): 61-68.
31. Unger Th Angiotensin receptors. J Hypertens1996; 14 (Suppl 5); S95-S103.
32. Timmermans PBMWM Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 32: 135-165.
33. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 1991; 12: 55-61.
34. Obermüller N Distribution of angiotensin II receptor subtypes in rat brain nuclei. Neurosci Lett1991; 132: 11-15.
35. Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (ATI and AT2) in rat brain. Am J Physiol 1991; 261: R209-R216.
36. Timmermans PB Angiotensin II receptor sub- types. Am J Hypertens 1992; (Suppl 6, pt 1): 406-410.
37. Kakar SS Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochem Biophys Res Commun 1992; 183: 1090-1096.
38. Sandberg K Cloning and expression of a novel angiotensin II receptor subtype. J Biol Chem 1992; 267(14): 9455-9458.
39. Furata H. Nucleotide sequence of a gene encoding human angiotensin II type-1 receptor. Direct sequence submission to the EMBL/GenBank/DDBJ databases. 7 November 1991.
40. Bergsma DJ Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992; 183: 989-995.
41. Kuroda SI Novel subtype of human angiotensin II type 1 receptor: cDNA cloning and expression. Biochem Biophys Res Commun 1994; 199: 467-474.
42. Kakar SS, Riel KK, Neill JD. Differential expression of angiotensin II receptor subtype mRNAs (AT-1A and AT-IB) in the rat brain. Biochem Biophys Res Commun 1992; 185: 688-692.
43. Kitami Y Differential gene expression and regulation of type-1 angiotensin II receptor subtypes in the rat. Biochem Biophys Res Commun 1992; 188: 446- 452.
44. Hahn AW, Jonas U, Buehler FR, Resink TJ. Identification of a fourth angiotensin ATI receptor subtype in rat. Biochem Biophys Res Commun 1993; 192: 1260- 1265.
45. Guo DF, Furata H, Mizukoshi M, Inagami T. The genomic organization of human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1994; 200: 313-319.
46. Curnow KM Alternatively spliced human type 1 angiotensin II receptor mRNAs are translated at different efficiencies and encode two receptor isoforms. Mol Endocrinol 1995; 9: 1250-1262.
47. Curnow KM. Human type-1 angiotensin II (ATI) receptor gene structure and function. Clin Exp Pharmacol Physiol Suppl 1996; 3: S67-S73.
48. Takeuchi K Molecular structure and transcriptional function of the rat vascular AT la angiotensin receptor gene. Circ Res 1993; 73: 612-621.
49. Landford K, Frenzel K, Martin BM, Bernstein KE. The genomic organization of the rat ATI angiotensin receptor. Biochem Biophys Res Commun 1992; 183: 1025- 1032.
50. Murasawa S, Matsubara H, Urakami M, Inada M. Regulatory elements that mediate expression of the gene for the angiotensin II type la receptor for the rat. J Biol Chem 1993; 268: 26996-27003.
51. Guo DF, Inagami T. The genomic organization of the rat angiotensin II receptor AT lb. Biochim Biophys Acta 1994; 1218: 91-94.
52. 2 receptors do not interact with guanine nucleotide binding proteins. Eur J Pharmacol 1991; 207: 157-163.
53. Garrison JC, Johnson DE, Campanile CP. Evidence for the role of phosphorylase kinase, protein kinase C and other Ca2+-sensitive protein kinases in the response of hepatocytes to angiotensin II and vasopressin. J Biol Chem 1988; 259: 3283-3292.
54. Buisson B The angiotensin II AT2 receptor modulates T-type calcium current in non-differen- tiated NG 108-15 cells. FEBS Lett 1992; 309: 161-164.
55. Cockcroft S, Thomas GM. Inositol-lipid-specific phos- pholipase C isoenzymes and their differential regulation by receptors. Biochem J 1992; 288 (Pt 1): 1-14.
56. Marrero MB Angiotensin II stimulates tyrosine phosphorylation of phospholipase C-gamma 1 in vascular smooth muscle cells. J Biol Chem 1994; 269: 10935-10939.
57. Marrero MB Ang II-induced tyrosine phosphorylation stimulates phospholipase C-gamma 1 and Cl- channels in mesangial cells. Am J Physiol 1996; 270 (6 Pt 1): C1834-C1842.
58. Ishida M Angiotensin II activates pp60c-src in vascular smooth muscle cells. Circ Res 1995; 77: 1053-1059.
59. Kawahara Y Angiotensin II induced expression of the c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem Biophys Res Commun1988; 150: 52-59.
60. Brechler V, Reichlin S, deGasparo M, Bottari SP. Angiotensin II stimulates protein tyrosine phosphatase activity through a G-protein independent mechanism. Receptors and Channels 1994; 2: 89-97.
61. Stouffer GA, Owens GK. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor j8,. Circ Res 1992; 70: 820-828.
62. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264(5164): 1415-1421.
63. Marrero MB Direct stimulation of Jak/STAT pathway by the angiotensin II ATI receptor. Nature 1995; 375(6528): 247-250.
64. Taubman MB Angiotensin II induces c-fos mRNA in aortic smooth muscle. Role of Ca2+ mobilization and protein kinase C activation. J Biol Chem 1989; 264(1): 526-530.
65. Marrero MB Direct stimulation of Jak/STAT pathway by the angiotensin II ATI receptor. Nature 1995; 375(6528): 247-250.
66. Bhat GJ Angiotensin II stimulates sis-inducing factor-like DNA binding activity. Evidence that the ATI A receptor activates transcription factor-Stat91 and/or a related protein. J Biol Chem 1994; 269(50): 31443-31449.
67. McWhinney CD The type I angiotensin II receptor couples to Stati and Stat3 activation through Jak2 kinase in neonatal rat cardiac myocytes. J Mol Cell Cardiol 1997; 29: 2513-2524.
68. Marrero MB et al. Role of Janus kinase/signal transducer and activator of transcription and mitogen-acti- vated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 1997; 272(39): 24684-24690.
69. Ali MS Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II ATI receptor. J Biol Chem 1997; 272(37): 23382-23388.
70. Pan J et al. Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart. Circ Res 1997; 81: 611 - 617.
71. Kambayashi Y, Bardhan S, Tahahashi K et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition.; Biol Chem 1993; 268: 24543-24546.
72. Mukoyama M Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven- transmembrane receptors. J Biol Chem 1993; 268: 24539-24542.
73. Hein L, Dzau VJ, Barsh GS. Linkage mapping of the angiotensin AT2 receptor gene (Agtr2) to the mouse X chromosome. Genomics 1995; 30: 369-371.
74. Lazard D Molecular characterization and chromosome localization of a human angiotensin II AT2 receptor gene highly expressed in fetal tissues. Receptors Channels 1994; 2: 271-280.
75. Martin MM, Su B, Elton TS. Molecular cloning of the human angiotensin II type 2 receptor cDNA. Biochem Biophys Res Commun 1994; 205: 645-651.
76. Ichiki T, Inagami T. Expression, genomic organization, and transcription of the mouse angiotensin II type 2 receptor gene. Circ Res 1995; 76: 693-700.
77. Kang J, Posner P, Sumners C. Angiotensin II type 2 receptor stimulation of neuronal K+ currents involves an inhibitory GTP binding protein. Am J Physiol 1994; 267: C1289-C1397.
78. Bottari SP The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate. Biochem Biophys Res Commun 1992; 183: 206-211.
79. Grady EF Expression of AT2 receptors in the developing rat fetus. J Clin Invest 1991; 88(3): 921- 933.
80. Metsärinne KP Angiotensin II is antiproliferative for coronary endothelial cells in vitro. Pharm Pharmacol Lett 1992; 2: 150-152.
81. Stoll M The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-657.
82. Stoll M, Steckelings UM, Bottari SP, Unger Th. Regulation of endothelial growth: role of the angiotensin II AT2-receptor. Circulation 1993; 88 (Suppl. 4, part 2): 1469 (abstr.).
83. Meffert S, Stoll M, Unger Th. The AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells in the presence of EGF and NGF. Nau- nyn-Schmiedeberg's Arch of Pharmacol 1995; 351 (Suppl): 471 (abstr.).
84. Nakajima M The angiotensin type 2 (AT2) receptor antagonizes the growth effects of the ATI receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci 1995; 92: 10663-10667.
85. Stauss HM Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bra- dykinin versus angiotensin II. JCardiovasc Risk 1994; 1: 255-262.
86. Gohlke P Chronic angiotensin ATI receptor blockade improves cardiac function and metabolism in SHRSP. Hypertension 1995; 25(3): 27 (abstr.).
87. Timmermans PBMWM Ang II receptors and Ang II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
88. Scheuer DA, Perrone MH. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 1993; 33: R917-R923.
89. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 1996; 27(2): 760-765.
90. Ichiki T Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995; 377: 748-750.
91. Hein L Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 1995; 377: 744-747.
92. Wong PC Nonpeptide Ang II receptor antagonists. XI. Pharmacology of EXP3174, an active metabolite of DuP753 - an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255: 211-217.
93. Wong PC Nonpeptide Ang II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 726-732.
94. Weinstock J l-(Carboxybenzyl)imidazole-5- acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem 1991; 34: 1514 - 1517.
95. Chiu AT Nonpeptide Ang II receptor antagonists VII. Cellular and biochemical pharmacology of DuP 753, on orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 711-718.
96. Lo MW Pharmacokinetics of losartan, an Ang II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-649.
97. Christ DD. Human plasma protein binding of the Ang II receptor antagonist losartan potassium (DuP753/MK954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 1995; 35: 515-520.
98. Sica DA The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995; 13 (Suppl 1): S49-S52.
99. Smith MC The effects of Ang II receptor block-ade with losartan on systemic blood pressure and renal and extrarenai prostaglandin synthesis in women with essential hypertension. Am J Hypertens1995; 8: 1177-1183.
100. Nakashima M, Uematsu T, Kosuge K. Pilot study of the uricosuric effect of DuP-753, a new Ang II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-335.
101. Criscione L et al. Valsarían: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardlovasc Drug Rev 1995; 13: 230-250.
102. Marino MR, Langenbacher KM, Ford NF, Uderman HD. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998; 38: 246-255.
103. Ojima M Candesartan (CV-11974) dissociates slowly from the angiotensin ATI receptor. Eur J Pharmacol 1997; 319: 137-146.
104. Noda M Inhibition of rabbit aortic angiotensin II (All) receptor by CV-11974, a new nonpeptide All antagonist. Biochem Pharmacol 1993; 46: 311-318.
105. Shibouta Y Pharmacological profile of a highly potently and long-acting angiotensin II receptor antagonist, 2-ethoxy-1 - [[2 ' - (1 H-tetrazol-5-yl) biphenyl - 4-yl] methyl] -1 H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-l-(cyelo- hexyloxycarbonyloxy)(-ethyl 2-ethoxy-1 -[[2' -(1 H-tetra- zol-5-yl)biphenyl-4-yl]methyl]-lH-benzim- idazole-7- carboxylate (TCV-116)). J Pharmacol Exp Ther 1993; 266(1): 114-120.
106. Morimoto S, Ogihara T. TCV-116: a new angiotensin II type-1 receptor antagonist. Cardiovasc Drug Rev1994; 12: 153-164.
107. Hübner R, Högemann AM, Sunzel M, Riddel JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.HumHypertens 1997; 11 (Suppl 2): S19-S25.